Seguridad de las vacunas contra la COVID-19

dc.contributor.authorNataniel Aldo Chaparro Mérida
dc.contributor.authorDayany Moreno Samper
dc.contributor.authorAlex Omar Franco Lacato
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:39:33Z
dc.date.available2026-03-22T14:39:33Z
dc.date.issued2021
dc.descriptionCitaciones: 12
dc.description.abstractThe development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest.
dc.identifier.doi10.17843/rpmesp.2021.384.9308
dc.identifier.urihttps://doi.org/10.17843/rpmesp.2021.384.9308
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/47798
dc.language.isoes
dc.publisherNational Institute of Health of Peru
dc.relation.ispartofRevista Peruana de Medicina Experimental y Salud Pública
dc.sourceFundación PROINPA
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectMedicine
dc.subjectPandemic
dc.subjectAdverse effect
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subject2019-20 coronavirus outbreak
dc.subjectHumanities
dc.titleSeguridad de las vacunas contra la COVID-19
dc.typearticle

Files